OpenAI 收购 Orchestra Bio，并入生命科学平台 Rosalind
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI 收购帮助药企协调药物研发的初创公司 Orchestra Bio，并将其并入面向生命科学的 AI 平台 Rosalind。Orchestra 的智能体可跟踪临床试验、在出现失败批次等问题时标记受影响的时间线，并给出后续选项。OpenAI 称此举意在构建把科学发现与临床试验、决策衔接起来的 AI 智能体，以加快新药上市；美国一款新药平均研发周期为 10 到 15 年，交易金额未披露。
推荐理由
AI 评分 69
OpenAI 将 Orchestra 并入生命科学平台 Rosalind，读者可据此了解其智能体在药物研发流程中的具体切入点。
主题
正文
OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio , a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind , OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.
The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.
Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.